In a major development, JDRF entered into a novel collaborative agreement with the Genomics Institute of the Novartis Research Foundation (GNF) to create a diabetes drug discovery and development platform. The four-year program is one of the largest and most comprehensive collaborations in the 40-year history of JDRF. It marks a major opportunity to work with an experienced and highly regarded scientific partner to quickly translate discoveries in research into therapeutics—drugs, compounds, and treatments for people with type 1 diabetes. Based in San Diego, GNF was founded in 1999 by the Novartis Research Foundation. “This agreement with GNF opens exciting new avenues for JDRF to speed the translation of basic research into drugs and treatments for type 1 diabetes,” said Alan J. Lewis, Ph.D., President and Chief Executive Officer of JDRF. The JDRF-GNF partnership should jumpstart the creation of a multi-product pipeline for beta cell regeneration, a therapeutic priority for JDRF.